Wedbush says Spyre Therapeutics will likely do well but has cut its price target from $123 to $120.

SYRE · Spyre Therapeutics

The AI's read

The rating still signals confidence, but the lower price estimate points the other way. Neither detail reports a change in Spyre's medicines, trials, or finances, so the report does not show a clear change in the company's outlook.